Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chloroquine
Drug ID BADD_D00440
Description Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria.[A191655] It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine].[A191787] Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis.[A192432] **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.[L14312]** Chloroquine was granted FDA Approval on 31 October 1949.[L12054]
Indications and Usage For the suppressive treatment and for acute attacks of malaria due to P. vivax, P.malariae, P. ovale, and susceptible strains of P. falciparum, Second-line agent in treatment of Rheumatoid Arthritis
Marketing Status Not Available
ATC Code P01BA01
DrugBank ID DB00608
KEGG ID D02366
MeSH ID D002738
PubChem ID 2719
TTD Drug ID D09EGZ
NDC Product Code Not Available
Synonyms Chloroquine | Chlorochin | Chingamin | Khingamin | Nivaquine | Chloroquine Sulfate | Sulfate, Chloroquine | Chloroquine Sulphate | Sulphate, Chloroquine | Aralen | Arequin | Arechine
Chemical Information
Molecular Formula C18H26ClN3
CAS Registry Number 54-05-7
SMILES CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Visual acuity reduced17.17.01.011; 06.02.03.0010.000699%
Visual field defect17.17.01.001; 06.02.07.0030.000466%Not Available
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.0030.001398%
Mental status changes19.07.01.0010.000466%Not Available
Cardiotoxicity12.03.01.007; 02.01.01.0020.001165%Not Available
Hypoacusis04.02.01.006--
Brain death08.04.01.004; 17.02.03.0030.000122%Not Available
Transaminases increased13.03.01.0150.000699%Not Available
Congestive cardiomyopathy02.04.01.0030.000932%Not Available
Retinal injury12.01.04.002; 06.11.01.001--Not Available
Electrocardiogram change13.14.05.014--Not Available
Ocular toxicity06.11.01.006; 12.03.01.0310.000466%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Psychotic disorder19.03.01.002--
Acute kidney injury20.01.03.0160.001165%
Macular pigmentation06.09.03.0150.000466%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000182%
Cyanosis central22.02.02.012; 02.01.02.0160.000466%Not Available
Flashback19.10.02.0090.000466%Not Available
PO2 increased13.02.01.0310.000466%Not Available
Post-traumatic stress disorder19.06.06.0020.000466%Not Available
Pupil fixed17.02.11.008; 06.05.03.0120.000466%Not Available
Respiratory rate increased13.15.01.0040.000466%Not Available
Right-to-left cardiac shunt03.07.10.004; 24.08.03.008; 22.06.01.0080.000699%Not Available
The 5th Page    First    Pre   5    Total 5 Pages